However, further RCTs with longer follow-up and a larger sample size should be conducted to verify whether the tumour immune cell PD-L1 as a biomarker has predictive and prognostic value in advanced UC patients treated with immune checkpoint inhibitors. Here, CD274 is linked to neoplasm.